Internal Medicine Doctors in S Weymouth, MA Accepting Medicare

6 Internal Medicine doctors found. Showing 1 - 6

Dr. Meredith Faggen, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 414, S Weymouth, MA 02190 Phone: 781-952-1650    Fax: 781-331-4936

Sarah Sulzner, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 400, S Weymouth, MA 02190 Phone: 781-340-1702

Paul J Duggan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 541 Main St, Suite 210, S Weymouth, MA 02190 Phone: 781-952-1280    Fax: 781-952-1570

Maria Antonia Depina, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 541 Main St Ste 400, S Weymouth, MA 02190 Phone: 781-952-1280

Michael P Duggan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 210, S Weymouth, MA 02190 Phone: 781-952-1280    Fax: 781-952-1570

Dr. Mark I Furman, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Fogg Rd, Cardiovascular Center At South Shore Hospital, S Weymouth, MA 02190 Phone: 781-624-8399    Fax: 781-624-5425

News Archive

Researchers develop new ‘visual biofeedback' system for speech therapy

A team of researchers in the GIPSA-Lab and at INRIA Grenoble Rhône-Alpes has developed a system that can display the movements of our own tongues in real time.

New study aims to develop nucleoside therapy as treatment for mitochondrial depletion syndromes

Hundreds of types of mitochondrial disease affect up to 38 million people worldwide, yet there are very few effective treatments, forcing patients and doctors to rely on symptom management to battle the serious and potentially fatal genetic disorder that starves the body's cells of energy.

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

IP 751 a marijuana-derived drug effectively suppresses pain and bladder overactivity in hypersensitive bladder disorders

IP 751, a potent synthetic analog of a metabolite of THC-the principal active ingredient of marijuana-effectively suppresses pain and bladder overactivity in hypersensitive bladder disorders such as interstitial cystitis (IC), according to animal model study results presented today at the annual meeting of the International Continence Society.

Read more Medical News

› Verified 8 days ago